The global multiple sclerosis drugs market was valued at USD 22.3 Billion in 2025 and is projected to reach USD 39.7 Billion by the end of 2036, expanding at a CAGR of 5.4% from 2026 to 2036. Market growth is driven by the rising prevalence of multiple sclerosis worldwide, advancements in disease-modifying therapies, increasing adoption of oral and high-efficacy treatments, and growing demand for personalized long-term disease management.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1130

Market Overview

Multiple sclerosis (MS) is a chronic neurological disease that affects the central nervous system, potentially causing inflammation, damage to the protective myelin sheath, and progressive neurological disability. Treatment typically involves disease-modifying therapies (DMTs), which help reduce relapses and disease activity, alongside medications that manage specific symptoms.

The multiple sclerosis drugs market includes injectable, oral, and infusion-based treatments designed for different disease types and patient needs. Growing awareness, improved diagnostic capabilities, and greater access to specialist neurological care are contributing to increased treatment uptake.

Analysis of Key Players in Multiple Sclerosis Drugs Market

The global multiple sclerosis drugs market comprises leading pharmaceutical companies and biotechnology developers competing through product innovation, clinical research, strategic partnerships, and portfolio expansion.

Key companies operating in the market include:

• Biogen Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck KGaA
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• AbbVie Inc.

Major manufacturers focus on developing high-efficacy therapies, improving existing formulations, and expanding treatment options for relapsing and progressive forms of MS. Companies are also exploring biosimilars and generic alternatives to improve affordability and broaden patient access.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html

Market Segmentation

By Drug Class
• Interferon Beta
• Sphingosine 1-Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Monoclonal Antibodies
• Corticosteroids
• Adrenocorticotropic Hormone
• Others

By Disease Type
• Relapsing-Remitting MS (RRMS)
• Primary-Progressive MS (PPMS)
• Secondary-Progressive MS (SPMS)
• Progressive-Relapsing MS (PRMS)

By Route of Administration
• Parenteral
• Oral

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453